Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesChronic Kidney Disease
You have accessRestricted Access

Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease

Sankar D. Navaneethan, Jesse D. Schold, Susana Arrigain, Stacey E. Jolly, Edgard Wehbe, Rupesh Raina, James F. Simon, Titte R. Srinivas, Anil Jain, Martin J. Schreiber and Joseph V. Nally
CJASN October 2011, 6 (10) 2395-2402; DOI: https://doi.org/10.2215/CJN.03730411
Sankar D. Navaneethan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesse D. Schold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana Arrigain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacey E. Jolly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edgard Wehbe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rupesh Raina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James F. Simon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Titte R. Srinivas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anil Jain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin J. Schreiber Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph V. Nally Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Flow chart showing how patients were selected for this analysis from the electronic-health-record-based registry. CKD, chronic kidney disease; eGFR, estimated GFR.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Kaplan–Meier survival curve based on serum bicarbonate levels among chronic kidney disease patients.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Associations (log hazard and 95% confidence interval) between all-cause mortality and baseline serum bicarbonate levels. Model adjusted for age, gender, African-American race, body mass index, diabetes, hypertension, hyperlipidemia, malignancy, congestive heart failure, cerebrovascular disease, and coronary artery disease at chronic kidney disease diagnosis and estimated GFR, use of renin-angiotensin system blockers and diuretics, hemoglobin and albumin.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Hazard ratio and 95% confidence interval (CI) of all-cause mortality associated with low serum bicarbonate levels among select subgroups. eGFR, estimated GFR.

Tables

  • Figures
  • Additional Files
    • View popup
    Table 1.

    Characteristics of patients serum bicarbonate levels measured at CKD diagnosis

    VariableaNot Measured (n = 2400)Low Bicarbonate (<23 mmol/L) (n = 5796)Normal Bicarbonate (23–32 mmol/L) (n = 35,301)High Bicarbonate (>32 mmol/L) (n = 652)
    Ageb (mean [SD])73.7 (9.8)68.9 (13.8)72.3 (11.5)71.9 (12.2)
    eGFRb (mean [SD])47.0 (10.0)42.3 (12.2)48.3 (9.7)46.4 (10.9)
    eGFR stage
        Stage 3a (GFR 45 to 59 [%])63.848.169.763.7
        Stage 3b (GFR 30 to 44 [%])28.032.424.226.5
        Stage 4 (GFR 15 to 29 [%])8.219.56.19.8
    Male gender (%)52.649.645.543.3
    African American (%)8.918.512.216.1
    Diabetes (%)12.927.722.621.6
    Hypertension (%)79.387.689.784.8
    Coronary artery disease (%)14.820.923.226.1
    Cerebrovascular disease (%)7.89.39.58.6
    Congestive heart failure (%)2.59.18.621.9
    Malignancy (%)29.226.123.623.2
    Hyperlipidemia (%)72.971.779.575.2
    COPD (%)6.37.89.020.1
    Smoking (%)
        nonsmoker84.083.588.786.5
        smoker9.010.27.07.7
        missing information7.06.34.35.8
    BMI kg/m2 (%)
        <18.50.961.81.11.2
        18.5 to 24.923.824.323.128.1
        25 to 29.934.532.835.628.5
        30 to 34.919.720.321.115.6
        35 to 39.99.19.48.812.1
        > 404.76.95.89.2
        missing information7.44.54.35.2
    Albumin (g/dl)b (mean [SD])4.0 ± 0.514.0 ± 0.534.2 ± 0.414.1 ± 0.48
    Hemoglobin (g/dl) (mean [SD])12.9 ± 1.812.1 ± 2.013.0 ± 1.712.8 ± 1.9
    • Overall serum bicarbonate groups <23, 23 to 32, and >32 significantly different with P < 0.001 for all variables except cerebrovascular disease. The chi-squared test was used to assess categorical variables and ANOVA used for continuous variables. CKD, chronic kidney disease; eGFR, estimated GFR; COPD, chronic obstructive pulmonary disease; BMI, body mass index.

    • a Chi-squared test, P < 0.05, unless otherwise noted, comparing patients with serum bicarbonate measured versus all those not measured.

    • b t-test, P < 0.05, comparing patients with serum bicarbonate measured versus all those not measured.

    • View popup
    Table 2.

    Factors associated with low serum bicarbonate and high serum bicarbonate at CKD diagnosis

    EffectModel 1 (n = 37,346)Model 2 (n = 32,623)
    Low Bicarbonate (<23 mmol/L) OR (95% CI)PHigh Bicarbonate (>32 mmol/L) OR (95% CI)P
    Age quintiles<0.010.09
        62.4 to 70.1 versus 18 to 62.40.72 (0.66, 0.79)0.79 (0.61, 1.02)
        70.2 to 76.4 2 versus 18 to 62.40.63 (0.58, 0.70)0.71 (0.55, 0.93)
        76.4 to 82.3 versus 18 to 62.40.57 (0.52, 0.63)0.82 (0.63, 1.06)
        82.3 to 104 versus 18 to 62.40.50 (0.45, 0.55)0.73 (0.56, 0.96)
    Male gender1.32 (1.23, 1.40)<0.010.94 (0.79, 1.11)0.46
    African-American race versus others1.24 (1.14, 1.35)<0.011.09 (0.86, 1.37)0.49
    BMI group (kg/m2)0.17<0.01
         <18.5 versus 18.5 to 24.91.28 (1.00, 1.63)0.82 (0.40, 1.68)
        25 to 29.9 versus 18.5 to 24.90.96 (0.89, 1.04)0.71 (0.57, 0.88)
        30 to 34.9 versus 18.5 to 24.90.96 (0.87, 1.05)0.67 (0.51, 0.86)
        35 to 39.9 versus 18.5 to 24.90.94 (0.84, 1.07)1.17 (0.88, 1.56)
        40+ versus 18.5 to 24.90.88 (0.77, 1.02)1.16 (0.83, 1.62)
        missing versus 18.5 to 24.91.03 (0.87, 1.21)0.97 (0.65, 1.46)
    eGFR (per 10-ml/min per 1.73 m2 increase)0.66 (0.64, 0.67)<0.010.92 (0.85, 0.998)0.046
    Diabetes1.20 (1.11, 1.29)<0.010.79 (0.64, 0.98)0.03
    Hypertension1.03 (0.93, 1.14)0.540.71 (0.56, 0.90)0.04
    Hyperlipidemia0.79 (0.73, 0.85)<0.010.84 (0.69, 1.03)0.10
    Coronary artery disease0.94 (0.87, 1.02)0.121.13 (0.92, 1.38)0.25
    Congestive heart failure0.82 (0.73, 0.91)<0.012.57 (2.08, 3.16)<0.01
    COPD0.88 (0.78, 0.98)0.0192.52 (2.05, 3.09)<0.01
    Smoking<0.010.77
        yes versus no1.38 (1.24, 1.54)0.92 (0.67, 1.27)
        missing versus no1.28 (1.12, 1.47)1.10 (0.75, 1.60)
    Hb per 1 g/dl increase0.83 (0.82, 0.85)<0.011.01 (0.96, 1.06)0.83
    Albumin per 1 mg/dl increase0.79 (0.74, 0.84)<0.010.71 (0.59, 0.86)<0.01
    • Model was additionally adjusted for the year of inclusion in the registry. CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval; BMI, body mass index; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease.

    • View popup
    Table 3.

    Associations between serum bicarbonate levels and all-cause mortality among chronic kidney disease patients

    Bicarbonate GroupUnadjusted HR [95% CI] (n = 41,445)Model A HR [95 %CI] (n = 41,445)Model B HR [95 %CI] (n = 37,687)Model C HR [95% CI] (n = 37,687)
    <23 mmol/L versus 23 to 32 mmol/L1.65 (1.56, 1.75)1.75 (1.65, 1.85)1.35 (1.27, 1.44)1.23 (1.16, 1.31)
    >32 mmol/L versus 23 to 32 mmol/L2.12 (1.86, 2.42)2.08 (1.83, 2.37)1.76 (1.54, 2.02)1.74 (1.52, 2.00)
    • Model A adjusted for age, gender, and race. Model B adjusted variables included in Model A, plus body mass index, diabetes, hypertension, hyperlipidemia, malignancy, congestive heart failure, cerebrovascular disease, coronary artery disease, chronic obstructive pulmonary disease, history of angiotensin-converting enzyme/angiotensin receptor blocker prescription, history of diuretic prescription at chronic kidney disease diagnosis, and hemoglobin and albumin. Model C adjusted variables included in Model B, plus baseline estimated GFR. HR, hazard ratio; CI, confidence interval.

Additional Files

  • Figures
  • Tables
  • Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 6 (10)
Clinical Journal of the American Society of Nephrology
Vol. 6, Issue 10
1 Oct 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease
Sankar D. Navaneethan, Jesse D. Schold, Susana Arrigain, Stacey E. Jolly, Edgard Wehbe, Rupesh Raina, James F. Simon, Titte R. Srinivas, Anil Jain, Martin J. Schreiber, Joseph V. Nally
CJASN Oct 2011, 6 (10) 2395-2402; DOI: 10.2215/CJN.03730411

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease
Sankar D. Navaneethan, Jesse D. Schold, Susana Arrigain, Stacey E. Jolly, Edgard Wehbe, Rupesh Raina, James F. Simon, Titte R. Srinivas, Anil Jain, Martin J. Schreiber, Joseph V. Nally
CJASN Oct 2011, 6 (10) 2395-2402; DOI: 10.2215/CJN.03730411
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Incidence and Risk Factors for Dialysis Reinitiation among Patients with a History of Dialysis Dependency
  • Survey of Salary and Job Satisfaction of Transplant Nephrologists in the United States
  • Implications of Accumulated Cold Time for US Kidney Transplantation Offer Acceptance
Show more Original Articles

Chronic Kidney Disease

  • Urine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis
  • Potential Mechanisms Involved in Chronic Kidney Disease of Unclear Etiology
  • Age and the Course of GFR in Persons Aged 70 and Above
Show more Chronic Kidney Disease

Cited By...

  • CO2 combining power and outcomes in patients with acute ischaemic stroke or transient ischaemic attack
  • Influence of Medications Containing Acid Salts on Serum Bicarbonate in CKD
  • Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study
  • Mechanism of Hyperkalemia-Induced Metabolic Acidosis
  • Serum Bicarbonate Concentration and Cognitive Function in Hypertensive Adults
  • NBCe1-A Regulates Proximal Tubule Ammonia Metabolism under Basal Conditions and in Response to Metabolic Acidosis
  • Metabolic Acidosis and Subclinical Metabolic Acidosis in CKD
  • Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
  • Acidosis and Kidney Allograft Survival
  • Bicarbonate Concentration, Acid-Base Status, and Mortality in the Health, Aging, and Body Composition Study
  • Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings
  • CKD as a Model for Improving Chronic Disease Care through Electronic Health Records
  • Persistent High Serum Bicarbonate and the Risk of Heart Failure in Patients With Chronic Kidney Disease (CKD): A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study
  • Current Status of Bicarbonate in CKD
  • Mediterranean Diet, Kidney Function, and Mortality in Men with CKD
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire